These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 39043605)

  • 1. Impact of LAG-3/FGL1 pathway on immune evasive contexture and clinical outcomes in advanced urothelial carcinoma.
    Yoshida T; Nakamoto T; Atsumi N; Ohe C; Sano T; Yasukochi Y; Tsuta K; Kinoshita H
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39043605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.
    Shi X; Li CW; Tan LC; Wen SS; Liao T; Zhang Y; Chen TZ; Ma B; Yu PC; Lu ZW; Qu N; Wang Y; Shi RL; Wang YL; Ji QH; Wei WJ
    J Clin Endocrinol Metab; 2021 Jan; 106(1):120-132. PubMed ID: 33000173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8
    Guo M; Yuan F; Qi F; Sun J; Rao Q; Zhao Z; Huang P; Fang T; Yang B; Xia J
    J Transl Med; 2020 Aug; 18(1):306. PubMed ID: 32762721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of lymphocyte-activating gene 3 and T-cell immunoreceptor with immunoglobulin and ITIM domains in cutaneous melanoma and their correlation with programmed cell death 1 expression in tumor-infiltrating lymphocytes.
    Lee WJ; Lee YJ; Choi ME; Yun KA; Won CH; Lee MW; Choi JH; Chang SE
    J Am Acad Dermatol; 2019 Jul; 81(1):219-227. PubMed ID: 30880064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinoma.
    Vanguri RS; Smithy JW; Li Y; Zhuang M; Maher CA; Aleynick N; Peng X; Al-Ahmadie H; Funt SA; Rosenberg JE; Iyer G; Bajorin D; Mathews JC; Nadeem S; Panageas KS; Shen R; Callahan MK; Hollmann TJ
    J Pathol; 2023 Nov; 261(3):349-360. PubMed ID: 37667855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target.
    Qian W; Zhao M; Wang R; Li H
    J Hematol Oncol; 2021 Sep; 14(1):147. PubMed ID: 34526102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive immunophenotyping of solid tumor-infiltrating immune cells reveals the expression characteristics of LAG-3 and its ligands.
    Garman B; Jiang C; Daouti S; Kumar S; Mehta P; Jacques MK; Menard L; Manjarrez-Orduno N; Dolfi S; Mukherjee P; Rai SC; Lako A; Koenitzer JD; David JM
    Front Immunol; 2023; 14():1151748. PubMed ID: 37795090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LAG-3, TIM-3 and VISTA Expression on Tumor-Infiltrating Lymphocytes in Oropharyngeal Squamous Cell Carcinoma-Potential Biomarkers for Targeted Therapy Concepts.
    Wuerdemann N; Pütz K; Eckel H; Jain R; Wittekindt C; Huebbers CU; Sharma SJ; Langer C; Gattenlöhner S; Büttner R; Speel EJ; Suchan M; Wagner S; Quaas A; Klussmann JP
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3.
    Wang J; Sanmamed MF; Datar I; Su TT; Ji L; Sun J; Chen L; Chen Y; Zhu G; Yin W; Zheng L; Zhou T; Badri T; Yao S; Zhu S; Boto A; Sznol M; Melero I; Vignali DAA; Schalper K; Chen L
    Cell; 2019 Jan; 176(1-2):334-347.e12. PubMed ID: 30580966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of Co-inhibitory Receptor Expression in COVID-19 Infection Compared to Acute
    Herrmann M; Schulte S; Wildner NH; Wittner M; Brehm TT; Ramharter M; Woost R; Lohse AW; Jacobs T; Schulze Zur Wiesch J
    Front Immunol; 2020; 11():1870. PubMed ID: 32983106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1 and LAG-3 Dominate Checkpoint Receptor-Mediated T-cell Inhibition in Renal Cell Carcinoma.
    Zelba H; Bedke J; Hennenlotter J; Mostböck S; Zettl M; Zichner T; Chandran A; Stenzl A; Rammensee HG; Gouttefangeas C
    Cancer Immunol Res; 2019 Nov; 7(11):1891-1899. PubMed ID: 31484656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma.
    El Halabi L; Adam J; Gravelle P; Marty V; Danu A; Lazarovici J; Ribrag V; Bosq J; Camara-Clayette V; Laurent C; Ghez D
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):257-266.e3. PubMed ID: 33277223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age and sex have no impact on expression levels of markers of immune cell infiltration and immune checkpoint pathways in patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy.
    Holland BC; Sood A; Delfino K; Dynda DI; Ran S; Freed N; Alanee S
    Cancer Immunol Immunother; 2019 Jun; 68(6):991-997. PubMed ID: 30997535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
    Li W; Liu Z; Jin K; Shao F; Zeng H; Wang Y; Zhu Y; Xu L; Wang Z; Chang Y; Zhang W
    BMC Cancer; 2023 Jul; 23(1):661. PubMed ID: 37452272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy.
    Yanik EL; Kaunitz GJ; Cottrell TR; Succaria F; McMiller TL; Ascierto ML; Esandrio J; Xu H; Ogurtsova A; Cornish T; Lipson EJ; Topalian SL; Engels EA; Taube JM
    JAMA Oncol; 2017 Jul; 3(7):974-978. PubMed ID: 28334399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade.
    Zuo S; Wei M; Xu T; Kong L; He B; Wang S; Wang S; Wu J; Dong J; Wei J
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34949694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coadministration of iRGD peptide with ROS-sensitive nanoparticles co-delivering siFGL1 and siPD-L1 enhanced tumor immunotherapy.
    Wan WJ; Huang G; Wang Y; Tang Y; Li H; Jia CH; Liu Y; You BG; Zhang XN
    Acta Biomater; 2021 Dec; 136():473-484. PubMed ID: 34571271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab modifies regulatory T cells and co-inhibitory receptor expression on circulating T cells in psoriasis.
    Yu Y; Chen Z; Wang Y; Li Y; Lu J; Cui L; Yu Z; Ding Y; Guo C; Zhang X; Shi Y
    Int Immunopharmacol; 2021 Jul; 96():107722. PubMed ID: 33965878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and Prognostic Significance of LAG-3, TIGIT, VISTA, and IDO1 in Endometrial Serous Carcinoma.
    Chen H; Molberg K; Carrick K; Niu S; Rivera Colon G; Gwin K; Lewis C; Lea J; Panwar V; Zheng W; Castrillon DH; Lucas E
    Mod Pathol; 2024 Aug; 37(8):100532. PubMed ID: 38848896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer.
    Wang Y; Wang C; Qiu J; Qu X; Peng J; Lu C; Zhang M; Zhang M; Qi X; Li G; Hua K
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.